Among African immigrants in Melbourne, Victoria, Australia, we demonstrated lower geometric mean vitamin D levels in immigrants with latent tuberculosis infection than in those with no Mycobacterium tuberculosis infection (
); P p .007 such levels were also lower in immigrants with tuberculosis or past tuberculosis than in those with latent tuberculosis infection ( ). Higher vitamin D levels were associated P ! .001 with lower probability of any M. tuberculosis infection ( ) and lower probability of tuberculosis or past tu-P ! .001 berculosis (compared with latent tuberculosis infection;
). P p .001
High rates of Mycobacterium tuberculosis (MTB) infection and vitamin D deficiency have been reported in African immigrants
in Australia [1] [2] [3] , the United States [4, 5] , and Europe [6] . Vitamin D is known to have an important role in macrophage activation and the subsequent restriction of MTB growth [7] , and it has been implicated as a risk factor for tuberculosis (TB) [8] . An association between 25(OH) vitamin D (25[OH]D) levels and TB has been described in several case-control studies [9] [10] [11] [12] [13] [14] [15] . An association between 25(OH)D levels and latent tuberculosis infection (LTBI) has not been well described.
The Royal Melbourne Hospital (Melbourne, Victoria, Australia) is a major tertiary referral center for refugee health and for patients with MTB infection. In this study, we examined the association between 25(OH)D levels and MTB infection status in adult immigrants from sub-Saharan Africa who attended the outpatient infectious diseases and refugee health clinics at the hospital.
Methods. A retrospective audit of patients attending the Victorian Infectious Diseases Service outpatient clinics at the Royal Melbourne Hospital from 1 January 2003 through 30 June 2006 was performed. All patients born in a sub-Saharan African country were included, except for those identified as white or Asian. Information was extracted from the patients' medical records and from hospital pathology and radiology records.
Investigation for exposure to MTB included Mantoux and QuantiFERON-TB Gold (QFT-G; Cellestis) testing [16] . The decision regarding which tests to perform was made by the referring doctor and depended on access to rebatable QFT-G tests. Mantoux tests were performed by specifically trained nurses using 0.1 mL (10 U) of PPD (CSL); the results were interpreted by the nurses as well. QFT-G tests were performed by personnel at accredited pathology laboratories, according to the manufacturer's instructions.
TB status was classified as follows: TB was defined as microbiological or histological evidence of MTB infection and/or receipt of treatment for TB during the study period, past TB was defined as documentation of having completed treatment for TB, LTBI was defined as a positive Mantoux test result (diameter, у10 mm) and/or a positive QFT-G test result and no evidence of TB or history of TB, any MTB infection was defined as evidence of MTB infection (i.e., past TB, TB, or LTBI), and no MTB infection was defined as a negative Mantoux and/or QFT-G test result and neither current TB nor past TB. Patients in the TB and past TB groups were combined (TB/ past TB) for the analysis, because we were interested in those whose infection had progressed to TB.
Statistical analysis. Patients who had both MTB infection status and 25(OH)D levels documented were included in the analysis of associations between 25(OH)D level and MTB infection. Because the distribution of 25(OH)D levels was rightskewed, the data were log transformed for subsequent analysis. We compared geometric mean 25(OH)D levels in each of the 3 groups (no MTB infection, LTBI, and TB/past TB) using 2-sample Student's t tests. We then created 2 multivariable binary logistic regression models with the following outcome variables: (1) any MTB infection versus no MTB infection and (2) TB/ past TB versus LTBI. These models incorporated age, sex, du- ration of residence in Australia 11 year, and country of birth (East African countries vs. other African countries) a priori as covariates. Finally, we used 2 separate univariate binary logistic models to derive fitted values to graphically represent the relationship between 25(OH)D levels and probability of (1) any MTB infection and (2) TB/past TB (compared with LTBI). Statistical analysis was performed using Stata, version 9.0 (Stata).
Ethical considerations. To maintain confidentiality, patient names were not recorded. This work was performed as part of a clinic audit and, therefore, did not require approval from the hospital human research ethics committee.
Results. Discussion. Our study shows a strong association between vitamin D deficiency and MTB infection in African immigrants attending the infectious diseases clinics of a Melbourne tertiary care hospital. To our knowledge, this is the first study to clearly demonstrate an association between vitamin D deficiency and LTBI.
Our finding of moderate to severe 25(OH)D deficiency in 78% of patients with TB/past TB is similar to that reported for African patients receiving treatment for TB in London, United Kingdom [14, 17] . Reduced 25(OH)D levels have been reported in patients with TB, compared with healthy control subjects, in 7 case-control studies [9] [10] [11] [12] [13] [14] [15] , although the difference achieved a P value of !.05 in only 5 of these studies [10, 11, [13] [14] [15] . None of these studies reported excluding patients with LTBI from the control group, and in 2 studies, the control group consisted entirely of patients with LTBI [14, 15] . Our finding of a relationship between low 25(OH)D levels and the risk of TB/past TB, compared with LTBI, raises the possibility that 25(OH)D deficiency increases the risk of progression from LTBI to TB, although our study does not show causality.
The clinical association between probability of any infection due to MTB and 25(OH)D deficiency has not been well documented previously, although in the control group in the study by Grange et al. [12] in Indonesia, those who had a lower 25(OH)D level (!81 nmol/L) were more likely to have a positive tuberculin skin test result than were those who had a 25(OH)D level у81 nmol/L (86% vs. 40%;
). Our findings raise P ! .02 the possibility that adequate 25(OH)D levels may protect against primary infection due to MTB, and this is supported by the work of Martineau et al. [18] , in which a single dose of vitamin D improved immunity to mycobacteria in vitro in contacts of patients with TB.
The strengths of the study were the large number of patients included and the careful documentation of all forms of MTB infection. This allowed a more detailed analysis of the role of vitamin D deficiency in LTBI than has occurred in previous studies. The main limitation was the retrospective clinical audit design, which meant that not all patients had all variables of interest documented, including serum 25(OH)D level and MTB infection status. This may have affected the observed associations and would be overcome in a prospective study. A potential confounding factor is the effect of bacille Calmette-Guérin vaccination status (which was not recorded) on the results of Mantoux test results; however, the difference in geometric mean 25(OH)D levels remained statistically significant between the groups when QFT-G test results alone were used to determine LTBI status. Another limitation is that some patients may have been receiving vitamin D supplements at the time of having their serum 25(OH)D level measured. This may affect the associations shown, although overall vitamin D supplementation was more common in those with MTB infection.
There is increasing epidemiological and molecular evidence that vitamin D and MTB infection are intricately linked. Our study contributes to this evidence by documenting the inverse relationship between serum 25(OH)D levels and both the likelihood of having any MTB infection and the likelihood of having TB/past TB rather than LTBI. Now, the challenge is to perform appropriate studies to elucidate the role of vitamin D supplementation in (1) preventing MTB infection, (2) preventing progression from LTBI to TB, and (3) treating TB.
